| |
| Names | |
|---|---|
|
IUPAC name
5-(benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-4-amine;hydrochloride
| |
| Other names
List
| |
| Properties | |
| C17H20ClN5O2S | |
| Molar mass | 393.891 g/mol |
| Identifiers | |
| ChemSpider | |
|
PubChem CID
|
|
| UNII | |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
AVN-322 is a 5-hydroxytryptamine subtype 6 receptor antagonist manufactured by Avineuro Pharmaceuticals Inc. that could potentially be used to combat Alzheimer's disease and schizophrenia. AVN-322 also reverses the negative effects of scopolamine and MK-80.
The compound is a sister drug to AVN-101 and AVN-211, two similar compounds under trial for treating Alzheimer's.Phase I trials for the drug were initiated in 2009 by Avineuro, and completed in the spring of 2010. The trials showed that AVN-322 was tolerated in a range of doses without any adverse effects, and Avineuro released plans to commence Phase II trials later the same year. The plan for further trials was discontinued in 2013.